May look to bring Liraglutide via clinical trial waiver: Mazumdar-Shaw

Kiran outlines how being vertically integrated puts Biocon in a strong position

The peptides and GLP-1 class of drugs that are offering breakthrough treatment for diabetes and obesity are estimated to be a $100 billion global opportunity by 2030. As patents keep expiring, companies like Biocon are well positioned to make the most of this opportunity. Speaking to Sohini Das and Aneeka Chatterjee over a video call, Kiran Mazumdar Shaw, executive chairperson, Biocon & Biocon Biologics, outlines how being vertically integrated puts Biocon in a strong position. Edited excerpts.

The generics business has seen some pricing pressure in Q1FY25. What is the outlook?

I would rather not focus on pricing pressure